CN1158297C - 用于治疗的具有c-17烷基侧链和芳香a-环的甾族化合物 - Google Patents

用于治疗的具有c-17烷基侧链和芳香a-环的甾族化合物 Download PDF

Info

Publication number
CN1158297C
CN1158297C CNB008095175A CN00809517A CN1158297C CN 1158297 C CN1158297 C CN 1158297C CN B008095175 A CNB008095175 A CN B008095175A CN 00809517 A CN00809517 A CN 00809517A CN 1158297 C CN1158297 C CN 1158297C
Authority
CN
China
Prior art keywords
norcholesta
hydroxy
group
formula
tetraene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB008095175A
Other languages
English (en)
Chinese (zh)
Other versions
CN1358193A (zh
Inventor
R��H�����˿���
R·H·赫斯
S
S·K·S·赛缇
¸
M·拉穆戈帕尔
3
S·库戈巴鲁索里拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Institute for Medicine and Chemistry Inc
Original Assignee
Research Institute for Medicine and Chemistry Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Institute for Medicine and Chemistry Inc filed Critical Research Institute for Medicine and Chemistry Inc
Publication of CN1358193A publication Critical patent/CN1358193A/zh
Application granted granted Critical
Publication of CN1158297C publication Critical patent/CN1158297C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Steroid Compounds (AREA)
CNB008095175A 1999-05-11 2000-05-11 用于治疗的具有c-17烷基侧链和芳香a-环的甾族化合物 Expired - Fee Related CN1158297C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9910934.0 1999-05-11
GBGB9910934.0A GB9910934D0 (en) 1999-05-11 1999-05-11 Chemical compounds

Publications (2)

Publication Number Publication Date
CN1358193A CN1358193A (zh) 2002-07-10
CN1158297C true CN1158297C (zh) 2004-07-21

Family

ID=10853250

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB008095175A Expired - Fee Related CN1158297C (zh) 1999-05-11 2000-05-11 用于治疗的具有c-17烷基侧链和芳香a-环的甾族化合物

Country Status (21)

Country Link
US (2) US6881730B1 (enExample)
EP (1) EP1179005B1 (enExample)
JP (1) JP2002544137A (enExample)
KR (1) KR100690040B1 (enExample)
CN (1) CN1158297C (enExample)
AT (1) ATE254629T1 (enExample)
AU (1) AU779743B2 (enExample)
CA (1) CA2373443A1 (enExample)
CZ (1) CZ297316B6 (enExample)
DE (1) DE60006665T2 (enExample)
DK (1) DK1179005T3 (enExample)
ES (1) ES2207509T3 (enExample)
GB (1) GB9910934D0 (enExample)
HK (1) HK1046001B (enExample)
HU (1) HUP0201047A3 (enExample)
IL (2) IL146442A0 (enExample)
NO (1) NO319949B1 (enExample)
NZ (1) NZ515482A (enExample)
PT (1) PT1179005E (enExample)
WO (1) WO2000068246A1 (enExample)
ZA (1) ZA200109272B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6908910B2 (en) 1993-08-06 2005-06-21 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents
GB9910934D0 (en) * 1999-05-11 1999-07-14 Res Inst Medicine Chem Chemical compounds
US7087592B1 (en) 1999-08-23 2006-08-08 Entre Med, Inc. Compositions comprising purified 2-methoxyestradiol and methods of producing same
DK1287017T3 (da) * 2000-05-11 2005-12-05 Res Inst Medicine Chem 2-substituerede pregna-1,3,5(10)-trien- og chola-1,3,5(10)-trienderivater og deres biologiske aktivitet
US6995278B2 (en) 2000-08-18 2006-02-07 Entre Med, Inc. Antiangiogenic agents
US7135581B2 (en) 2000-08-18 2006-11-14 Entremed, Inc. Antiangiogenic agents
WO2002042319A2 (en) * 2000-11-27 2002-05-30 Entremed, Inc. 2-substituted estrogens as antiangiogenic agents
WO2002092100A1 (en) * 2001-05-11 2002-11-21 Marsden, John, Christopher 17-(c(ch3) (ch2) o-3c (r4, r5) n (r6, r7))-substituted 19-nor-pregna-1, 3, 5(10)-triene derivatives and their medical use
CA2527074A1 (en) 2003-05-28 2005-04-07 Entremed, Inc. Antiangiogenic agents
US7498322B2 (en) 2004-03-12 2009-03-03 Entremed, Inc. Antiangiogenic agents
AU2007227256B2 (en) 2006-03-20 2012-10-04 Entremed, Inc. Disease modifying anti-arthritic activity of 2-methoxyestradiol
KR101598402B1 (ko) * 2007-06-19 2016-03-03 키쎄라 바이오파마슈티컬즈 인코포레이티드 합성 담즙산 조성물, 방법 및 제조물
JOP20180077A1 (ar) 2007-06-19 2019-01-30 Kythera Biopharmaceuticals Inc تركيبات وطرق لحمض صفراوي تخليقي
US20080318870A1 (en) 2007-06-19 2008-12-25 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
US8242294B2 (en) 2007-06-19 2012-08-14 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
CN107936076B (zh) * 2011-09-08 2021-10-15 萨奇治疗股份有限公司 神经活性类固醇、组合物、及其用途
MX362544B (es) 2013-03-13 2019-01-24 Sage Therapeutics Inc Esteroides neuroactivos y metodos para su uso.
EP4306114A1 (en) 2014-06-18 2024-01-17 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
EP3828194B1 (en) 2015-07-06 2025-04-16 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
HK1255500A1 (zh) 2015-07-06 2019-08-16 Sage Therapeutics, Inc. 氧固醇及其使用方法
PL3319612T3 (pl) 2015-07-06 2021-12-20 Sage Therapeutics, Inc. Oksysterole i sposoby ich stosowania
US20190330259A1 (en) 2016-04-01 2019-10-31 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
MD3481846T2 (ro) 2016-07-07 2021-11-30 Sage Therapeutics Inc 24-Hidroxisteroli 11-substituiți pentru utilizare în tratamentul stărilor legate de NMDA
CN121085986A (zh) 2016-09-30 2025-12-09 萨奇治疗股份有限公司 C7取代的氧固醇及其作为nmda调节剂的方法
KR102521573B1 (ko) 2016-10-18 2023-04-14 세이지 테라퓨틱스, 인크. 옥시스테롤 및 그의 사용 방법
TW202444381A (zh) 2016-10-18 2024-11-16 美商賽吉醫療公司 氧固醇(oxysterol)及其使用方法
CN115040524A (zh) * 2022-07-27 2022-09-13 深圳市中西医结合医院 4-胆甾烯-3-酮用于治疗多发性骨髓瘤骨病的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3562260A (en) * 1965-08-23 1971-02-09 Ormonoterapia Richter Spa 2-carbonyl-estratrienes and method of their preparation
GB1267915A (en) * 1968-05-24 1972-03-22 Glaxo Lab Ltd Ring a-substituted ring a-aromatic steroids
FR2528434B1 (fr) * 1982-06-11 1985-07-19 Roussel Uclaf Nouveaux 19-nor steroides substitues en 11b et eventuellement en 2, leur procede de preparation et leur application comme medicament
JP2623285B2 (ja) * 1988-03-09 1997-06-25 雪印乳業株式会社 ２（３―ハイドロキシ―１，３，５（１０）―エストリエン―１７―イル）プロピオン酸の製造法
GB9910934D0 (en) * 1999-05-11 1999-07-14 Res Inst Medicine Chem Chemical compounds
US6967195B2 (en) * 2000-05-11 2005-11-22 Research Institute For Medicine And Chemistry, Inc. 2-substituted pregna-1-3,5(10) triene and chola-1,3,5(10) triene derivatives and their biological activity

Also Published As

Publication number Publication date
HK1046001B (en) 2004-12-24
EP1179005A1 (en) 2002-02-13
CA2373443A1 (en) 2000-11-16
WO2000068246A1 (en) 2000-11-16
IL146442A (en) 2006-10-05
KR100690040B1 (ko) 2007-03-09
PT1179005E (pt) 2004-04-30
HK1046001A1 (en) 2002-12-20
IL146442A0 (en) 2002-07-25
EP1179005B1 (en) 2003-11-19
JP2002544137A (ja) 2002-12-24
CZ297316B6 (cs) 2006-11-15
ATE254629T1 (de) 2003-12-15
NO20015520L (no) 2002-01-09
ES2207509T3 (es) 2004-06-01
NO20015520D0 (no) 2001-11-12
CZ20014049A3 (cs) 2002-04-17
DE60006665T2 (de) 2004-10-07
DK1179005T3 (da) 2004-03-01
DE60006665D1 (de) 2003-12-24
US6881730B1 (en) 2005-04-19
NZ515482A (en) 2004-05-28
ZA200109272B (en) 2003-02-26
AU4596000A (en) 2000-11-21
GB9910934D0 (en) 1999-07-14
US20050171075A1 (en) 2005-08-04
AU779743B2 (en) 2005-02-10
KR20020013542A (ko) 2002-02-20
HUP0201047A3 (en) 2003-07-28
CN1358193A (zh) 2002-07-10
HUP0201047A2 (en) 2002-08-28
NO319949B1 (no) 2005-10-03

Similar Documents

Publication Publication Date Title
CN1158297C (zh) 用于治疗的具有c-17烷基侧链和芳香a-环的甾族化合物
CN1036342C (zh) 9，11-脱氢甾类化合物及9-α-羟基-16，17-脱氢甾类化合物的制备方法
CN1026236C (zh) 甾类5-α-还原酶抑制剂的制备方法
CN1057770C (zh) 19,11β－桥甾族化合物在制药中的应用
CN1042026C (zh) 维生素d系列的25羧酸衍生物、其制法及中间产物、含该衍生物的药物及其药用
CN1129441A (zh) 维生素d类似物
CN1231670A (zh) 7α－(ξ－氨基烷基)－雌三烯、其制备方法、含有7α－(ξ－氨基烷基)－雌三烯的药剂及其用于制备药物的应用
CN1187365C (zh) 9α－羟基－17－亚甲基甾类在制备皮质甾类中的用途
CN1151164A (zh) 用于调节减数分裂的甾醇衍生物
CN1269836C (zh) 用于改进抗炎治疗的细胞靶向的免疫细胞特异性大环内酯化合物与抗炎化合物的共轭物
CN1133296A (zh) 11β-芳基-4-雌烯及其药物上适宜的酸加成盐的制药应用
CN1085224A (zh) 氟化17β-取代的4-氮杂-5α-雄甾烷-3-酮衍生物
CN1177860C (zh) 胆烯酸酰胺及其药物组合物
HK1046145A1 (zh) 作為選擇性雌激素的16-羥基雌三烯
CN1653081A (zh) 甾族化合物的c－17螺甾内酯化和6,7氧化
CN1185249C (zh) 在11位带有烃取代基的非芳香族雌激素甾族化合物
CN1326461A (zh) 减数分裂调控化合物
CN1751059A (zh) 具有抗肿瘤活性的2－取代的雌－1,3,5(10)－三烯－3－基氨基磺酸酯
CN101061133A (zh) 制备17－羟基－6β,7β;15β,16β－双亚甲基－3－氧代－17α－孕甾－4－烯－21－羧酸γ－内酯的工业方法和用于该方法的关键中间体
CN1102529A (zh) 氟化4-氨基雄甾二烯酮衍生物及其制备方法
CN1196720A (zh) 新的维生素d类似物
CN1059529A (zh) 抗雄激素的[3，2-C]吡唑基和[3，2-d]三唑基类甾醇
CN1305890C (zh) 17α－氟烷基甾体、其制备方法以及包含这些化合物的药物组合物
CN1129577C (zh) 维生素d3衍生物
CN1659181A (zh) 作为选择性雌激素的9α－取代的雌三烯

Legal Events

Date Code Title Description
C06 Publication
C10 Entry into substantive examination
PB01 Publication
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20040721

Termination date: 20100511